Table 2 Favorable prognostic factors of progression-free and overall survival in patients with anaplastic oligodendroglioma.
Factors | Progression-free survival (n = 95) | Overall survival (n = 95) | ||||||
|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate (backward stepwise) | Univariate | Multivariate (backward stepwise) | |||||
p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | |
Sex (female) | 0.836 | 0.95 (0.56–1.60) | 0.780 | 0.92 (0.51–1.66) | ||||
Age (< 60 years) | 0.132 | 0.64 (0.35–1.15) | < 0.001* | 0.37 (0.19–0.61) | 0.703 | 1.02 (0.93–1.11) | ||
Frontal lobe tumor | 0.021* | 0.52 (0.29–0.91) | 0.919 | 0.92 (0.18–4.60) | 0.273 | 0.70 (0.38–1.32) | ||
No strong enhancement | 0.014* | 0.49 (0.27–0.88) | 0.876 | 0.90 (0.25–3.27) | 0.094 | 0.59 (0.31–1.10) | ||
Calcification | 0.448 | 0.81 (0.46–1.41) | 0.083 | 0.57 (0.30–1.09) | ||||
No periventricular involvement | 0.417 | 0.75 (0.37–1.52) | 0.459 | 0.76 (0.37–1.57) | ||||
Gross total resection | 0.038* | 0.57 (0.37–0.98) | 0.560 | 0.71 (0.22–2.24) | 0.148 | 0.66 (0.37–1.16) | ||
Methylated MGMT promoter | 0.089 | 0.29 (0.63–1.32) | 0.093 | 0.18 (0.02–1.72) | ||||
Adjuvant treatment | 0.695 | 0.77 (0.47–1.28) | 0.385 | 0.74 (0.42–1.30) | ||||
Ki-67 index < 20% | 0.029* | 0.52 (0.28–0.94) | 0.099 | 0.40 (0.14–1.18) | 0.010* | 0.42 (0.21–0.83) | 0.034* | 0.16 (0.28–0.87) |
1p/19q codeletion | < 0.001* | 0.30 (1.59–0.57) | 0.982 | 0.98 (0.16–5.91) | < 0.001* | 0.22 (0.11–0.45) | 0.234 | 4.06 (0.36–45.43) |
IDH1/2 mutation | < 0.001* | 0.25 (0.11–0.56) | 0.018* | 0.28 (0.10–0.80) | 0.004* | 0.26 (0.01–0.70) | 0.004* | 0.12 (0.03–0.51) |
